Becton, Dickinson and Co. (BDX) Financial Statements
Historical financial data — 43 statements covering FY2016–FY2025
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention produc...
Becton, Dickinson and Co.'s revenue increased 8.2% year over year, from $20.18B to $21.84B.
Net income decreased 1.6% over the same period, from $1.71B to $1.68B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 75% in total.
Total debt remained relatively stable at $19.18B.
The debt-to-equity ratio stands at 0.76, indicating a moderate leverage profile.
Operating cash flow declined 10.8% to $3.43B.
Becton, Dickinson and Co. maintains a moderate net profit margin of 7.7%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q4 FY2024 | $5.44B+9.0% | $400.0M | $2.49B | $622.0M | $1.18B | $57.29B | $20.11B | $25.89B |
| Q1 FY2025 | $5.17B-4.9% | $303.0M | $2.23B | $453.0M | $693.0M | $54.66B | $18.76B | $25.20B |
| Q2 FY2025 | $5.27B+2.0% | $308.0M | $2.26B | $547.0M | $164.0M | $54.47B | $19.27B | $25.24B |
| Q3 FY2025 | $5.51B+4.5% | $574.0M | $2.63B | $882.0M | $1.22B | $54.90B | $19.34B | $25.47B |
| Q4 FY2025 | $5.89B+6.9% | $493.0M | $2.80B | $697.0M | $1.35B | $55.33B | $19.18B | $25.39B |
| Q1 FY2026 | $5.25B-10.8% | $382.0M | $2.41B | $552.0M | $657.0M | $54.84B | $19.54B | $25.28B |
| Q2 FY2026 | $3.95B-24.8% | $-310.0M | $1.79B | $733.0M | $671.0M | $50.83B | $17.28B | $24.13B |
| Q3 FY2026 | $4.98B+26.2% | $377.0M | $2.31B | $-60.0M | $776.0M | $50.73B | $16.81B | $24.42B |
Balance Sheet Summary (Q3 FY2026)
Becton, Dickinson and Co. (BDX) Financial Statements & Revenue History
Becton, Dickinson and Co. (BDX) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry trading at $191.75 with a market capitalization of $52. This page provides 43 historical financial statements for Becton, Dickinson and Co., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Becton, Dickinson and Co. reported revenue of $21.8 billion, representing 8.2% year-over-year growth. The net profit margin of 7.7% indicates moderate profitability. The debt-to-equity ratio of 0.76 reflects moderate leverage.
BDX Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Becton, Dickinson and Co.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether BDX is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track BDX's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Becton, Dickinson and Co. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of BDX's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use BDX Financial Data
Investors use Becton, Dickinson and Co.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare BDX's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how BDX's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View BDX's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Becton, Dickinson and Co.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.BDX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.